Article Text

Download PDFPDF
Original research
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?
  1. Susanna Meade1,
  2. Emma Routledge1,
  3. Esha Sharma2,
  4. Sailish Honap1,
  5. Sebastian Zeki1,
  6. Shuvra Ray1,
  7. Simon H C Anderson1,
  8. Jeremy Sanderson1,
  9. Joel Mawdsley1,
  10. Peter M Irving1,
  11. Mark A Samaan1
  1. 1IBD Centre, Department of Gastroenterology, Guy's and St Thomas' Hospitals NHS Trust, London, UK
  2. 2Pharmacy Department, Guy's and Saint Thomas' Hospitals NHS Trust, London, UK
  1. Correspondence to Dr Susanna Meade, Gastroenterology, Guy's and St Thomas' Hospitals NHS Trust, London, London, UK; smeade{at}doctors.org.uk

Abstract

Objective The second iteration of the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) initiative recommends use of the Simple Endoscopic Score for Crohn’s disease (SES-CD) as a treatment target for patients with CD. We aimed to assess whether the STRIDE-II endoscopic endpoints are achievable and whether the degree of mucosal healing (MH) affects long-term outcomes.

Design/method We performed a retrospective observational study between 2015 and 2022. Patients with CD who had baseline and follow-up SES-CD scores after biological therapy initiation were included. The primary outcome was treatment failure, defined as the need for: (1) change of biological therapy for active disease (2) corticosteroid use (3) CD-related hospitalisation or (4) surgery. We compared rates of treatment failure with the degree of MH achieved. Patients were followed up until treatment failure or study end (August 2022).

Results 50 patients were included and followed up for median 39.9 (34.6–48.6) months. Baseline characteristics: 62% male, median age 36.4 (27.8–43.9) years, disease distribution (L1: 4, L2: 11, L3: 35, perianal: 18). The proportion of patients achieving STRIDE-II end-points were: SES-CD≤2–25 (50%) and >50% reduction in SES-CD—35 (70%). Failure to achieve SES-CD≤2 (HR 11.62; 95% CI 3.33 to 40.56, p=0.003) or >50% improvement in SES-CD (HR 30.30; 95% CI 6.93 to 132.40, p<0.0001) predicted treatment failure.

Conclusion Use of SES-CD is feasible in real-world clinical practice. Achieving an SES-CD≤2 or a greater than 50% reduction, as set out by STRIDE-II, is associated with reduced rates of overall treatment failure including CD-related surgery.

  • Crohn's disease
  • endoscopic procedures

Data availability statement

Data are available upon reasonable request. Data will be shared upon reasonable request to the authors.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. Data will be shared upon reasonable request to the authors.

View Full Text

Footnotes

  • Twitter @gastroDS, @SamaanMark

  • Contributors SM guarantor; MAS, SM, JM and SZ conception, design; SM, ER, SZ data collection, SM and MAS data analysis and interpretation; MAS, SM and ER manuscript drafting, SM, ER, ES, SH, SZ, SR, SHCA, JS, JM, PMI and MAS review, editing and final approval.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SM has received an educational grant from Pfizer and speaker fees from Dr Falk Pharma. SH received lecture fees from Pfizer, Janssen, and Takeda. JM has received advisory fees from Janssen, Galapagos, Abbvie and lecture fees from Janssen and Pfizer. PMI has received lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire and Pfizer. Financial support for research: MSD, Takeda and Pfizer. Advisory fees: Abbvie Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos Topivert, Genentech, Hospira, Samsung Bioepis. MAS has served as a speaker, a consultant and/or advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Samsung Bioepis. MAS has received advisory fees from Bristol-Myers Squibb, Janssen, Takeda, Sandoz, Samsung Bioepis, Galapagos, AbbVie, and has received lecture fees from Bristol-Myers Squibb, Janssen, Takeda, MSD, Falk, AbbVie, Galapagos.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.